Supplementary Figure 6 from Phase II window study of olaparib alone or with cisplatin or durvalumab in operable Head and Neck Cancer

Supplementary Figure 6. Posttreatment CD163 (by QIF) increase in three patients with concurrent increase in the CD163 transcripts. Representative images from a patient’s tumor tissue sample showing pre and post treatment (Durvalumab-Olaparib Arm) CD163 expression. Nuclei (blue), Cytokeratin (green), CD163 (yellow) and CSF1R (red).</p

Supplementary Table 4 from Phase II window study of olaparib alone or with cisplatin or durvalumab in operable Head and Neck Cancer

Table 4a. Fold-change values for each signature between Response and No Response based on physical examination, pathology or imaging Table 4b. Fold-change values for significantly differentially expressed genes between Response and No Response based on physical examination, pathology or imaging</p

Supplementary Figure 2 from Phase II window study of olaparib alone or with cisplatin or durvalumab in operable Head and Neck Cancer

Supplementary Figure 2. Differentially expressed signatures in Responders relative to no-Responders. Response is based on physical examination, pathology or imaging. Responders had higher scores in Inflammatory Chemokines and Exhausted CD8 Signatures, as well as PD-1, Cytotoxicity and CD45. The significance (p-value, P and adjusted p-value, Padj) is represented relative to Fold Change (FC) in the x-axis.</p

Supplementary Table 5 from Phase II window study of olaparib alone or with cisplatin or durvalumab in operable Head and Neck Cancer

Supplementary Table 5. Incidence of adverse events by maximum grade in the safety population.</p

Supplementary Materials and Methods from Phase II window study of olaparib alone or with cisplatin or durvalumab in operable Head and Neck Cancer

The details for the assays and image analysis are summarized in the Supplementary Materials and Methods.</p

Supplementary Figure 3 from Phase II window study of olaparib alone or with cisplatin or durvalumab in operable Head and Neck Cancer

Supplementary Figure 3. A. No significant differences in stromal TILs were found between pre- and post-treatment samples in all arms. In Arm D TILs were increased post-treatment in most of the samples (5 out of 7). Figures B and C show representative images of TILs in pre- and post-treatment samples respectively from one patient in Arm D, measured by QuPath v0.3.0. Figures show tissues before (left) and after (right) QuPath annotations. Color legend; red, tumor cells; purple, lymphocytes; green, fibroblasts; yellow, other; Cisplatin-Olaparib, C-O; Olaparib, O; Durvalumab-Olaparib, D-O</p

Supplementary Figure 4 from Phase II window study of olaparib alone or with cisplatin or durvalumab in operable Head and Neck Cancer

Supplementary Figure 4. Relative fold change (2-ΔΔCq) of PD-L1 in respect to Β2Μ (reference gene) in the CTC fraction for individual samples of HNSCC patients before (blue) and after (orange) therapy.</p

Supplementary Figure 5 from Phase II window study of olaparib alone or with cisplatin or durvalumab in operable Head and Neck Cancer

Supplementary Figure 5. Map showing the distribution of mutations per gene per tumor. Light and dark purple, green and orange indicate pre- and post-treatment samples for patients treated with cisplatin and olaparib, olaparib and durvalumab and olaparib only, respectively. Blues correspond to samples before and after second biopsy/surgery for patients who did not receive treatment.</p

Supplementary Table 1 from Phase II window study of olaparib alone or with cisplatin or durvalumab in operable Head and Neck Cancer

Supplementary Table 1a. Representativeness of Study Participants Supplementary Table 1b. Nanostring IO360 panel</p

Supplementary Table 3 from Phase II window study of olaparib alone or with cisplatin or durvalumab in operable Head and Neck Cancer

Supplementary Table 3. Genes with significanlty changes pre- and post-Olaparib based treatment</p